European CHMP recommends approval of use of anidulafungin in paediatric patients

Anidulafungin is currently approved for the treatment of invasive candidiasis in adult patients. The CHMP has issued a positive opinion, recommending the approval of an extension of its licensed indication, to include paediatric patients aged 1 month to <18 years.


European Medicines Agency